Picture of SK Biopharmaceuticals Co logo

326030 SK Biopharmaceuticals Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge CapSucker Stock

Annual cashflow statement for SK Biopharmaceuticals Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line64,846-139,431-35,379226,973253,254
Depreciation
Amortisation
Non-Cash Items-95,83835,8485,643-105,692-38,101
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-73,521-69,321-79,782-43,809-55,767
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities-92,872-159,920-94,20194,900176,334
Capital Expenditures-5,992-5,961-3,249-13,424-29,510
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items264,963-89,753228,5222,484-5,910
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities258,971-95,714225,273-10,941-35,420
Financing Cash Flow Items181-1,36012,1980.3770
Other Financing Cash Flow
Net Issuance / Retirement of Debt
Cash from Financing Activities-4,646134,9146,623-4,498-156,678
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash166,589-121,863135,64083,107-15,036